Moreover, limited stability and early release of labelled iodine from their conjugated VHH before reaching their target protein might limit clinical usefulness, as was shown for the application of 125I-labelled EGF in an in vivo model of an EGFR overexpressing tumor (54). This evidence concerns the gene EGF and neoplasm.